Their project’s new tracking method utilizes motion sensors in devices to analyze the heart’s movement, which affects tens of millions of people worldwide, poses serious health risks, and often requires repeated hospitalizations. It has the potential to revolutionize the diagnosis of heart failure.

Heart failure is characterized by the inability of the heart to effectively pump blood around the body and is caused by a variety of cardiovascular diseases, and is often difficult to diagnose.

While traditional diagnostic methods include laboratory tests, blood tests, and imaging tests, a new technology known as cardiac gyrography offers a non-invasive approach to detecting heart failure by measuring the vibrations of the heart in the chest. We provide

The researchers also said that by using motion sensors built into smartphones, they may be able to pick up subtle vibrations that may not be detected early even with a stethoscope. The integration of smartphone-based diagnostics could help develop more efficient and accessible medical solutions.

“The results obtained with this new method are promising and may make it easier to detect heart failure in the future,” said one of the study’s two lead authors, a professor at American University said cardiologist Antti Saraste, professor of cardiovascular medicine. Turku, Finland.

This study is the culmination of a decade of research collaboration between the two joint organizations.

A recent study they conducted at major medical institutions in Finland and the United States, including Turku University Hospital, Helsinki University Hospital, and Stanford University Hospital, involved approximately 1,000 participants, including 200 patients diagnosed with heart failure.

By comparing motion sensor data from patients with heart failure to those without heart failure, researchers were able to identify distinctive patterns associated with heart failure, and the potential for smartphone-based detection methods. demonstrated its effectiveness.

“In primary care, there are very limited tools to detect heart failure. We can create completely new treatment options,” said cardiologist Juuso Blomster, founding member and CEO of CardioSignal.